Schjesvold Fredrik

37PUBLICATIONS
156CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Apr 06, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

Francesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos

|Mar 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma.

Fredrik Schjesvold, Andrew Spencer, Yael C Cohen

|Mar 02, 2026
TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Karolos Douvlataniotis, Aleksei Titov, Julia Zeun

|Dec 22, 2025
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma.

Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen

|Oct 08, 2025
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone.

Luca Bertamini, Cathelijne Fokkema, Paula Rodriguez-Otero

|Jul 09, 2025
Targeting proteostasis in multiple myeloma through inhibition of LTK.

Thea Kristin Våtsveen, Mariaserena Giliberto, Valgerdur Bjornsdottir

Pageof 7

Frequent Collaborators

8 joint publications

Meletios-Athanasios Dimopoulos

8 joint publications

Annette Vangsted

7 joint publications

Pieter Sonneveld

6 joint publications

Tobias Schmidt Slørdahl